Allergan Pharmaceuticals International
Part of AbbVie
Company
Allergan Pharmaceuticals International develops one asset, in phase 1, no development reported (EDIT‐101 in Leber congenital amaurosis 10). Mostly gene editing acting on CEP290.
- 1
- Asset
- Furthest stage
- Phase 1, no development reported
- 0
- Trials
- 0
- Signals
Pipeline
1CRISPR gene editing removes a pathogenic intronic sequence in CEP290 to restore normal splicing in retinal photoreceptors.
Phase 1, no development reported, Gene editing, CEP290, Leber congenital amaurosis 10, eye disorders congenital, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Similar companies6